May 15, 2018 (Vol. 38, No. 10)

Sartorius Stedim Biotech

The ambr® 250 high-throughput perfusion, an automated parallel bioreactor system, has been specially designed for rapid cell culture perfusion process development to optimize production of therapeutic antibodies. Developed in collaboration with major biopharma companies, it combines 12 or 24 single-use perfusion mini-bioreactors (100–250 mL working volume) with associated single-use perfusion components, all controlled by one automated workstation. The combination of this multi-parallel processing capacity and fully single-use perfusion vessel enables scientists to perform more perfusion culture experiments in a fraction of the time and cost of using traditional perfusion-enabled benchtop bioreactors. This innovation supports a range of hollow-fiber perfusion applications, enabling Design of Experiments (DoE) studies for high-cell-density process development in a Quality by Design (QbD) approach.

Previous articleCommon Cold Blocked from Replicating by Novel Drug Molecule
Next articleNDF Identified as Critical Molecule for Facilitating Transcription through Nucleosomes